Chemotherapy-Induced Neutropenia Treatment Market Size was valued at USD 0.6 Billion in 2023. The Chemotherapy-Induced Neutropenia Treatment market industry is projected to grow from USD 0.7 Billion in 2024 to USD 0.9 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.00% during the forecast period (2024 - 2032). The rising number of cancer cases directly correlates with the incidence, which is the key market driver enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for Chemotherapy-Induced Neutropenia (CIN) Treatment is being driven by the growing aging population. As individuals age, their susceptibility to cancer increases, prompting a surge in chemotherapy utilization among older adults. Concurrently, elderly individuals undergoing chemotherapy face elevated risks of neutropenia and its ensuing complications, attributable to age-related immune function declines. This trend underscores an escalating demand for efficacious Chemotherapy-Induced Neutropenia (CIN) treatments aimed at mitigating neutropenic adversities and averting infections within this susceptible demographic. Furthermore, the persistent trajectory of an aging population accentuates the urgency for CIN remedies, propelling market expansion. Consequently, the imperative for tailored strategies in managing chemotherapy-induced neutropenia intensifies, driving an inexorable crescendo in demand for CIN treatments amidst the geriatric cohort's escalating healthcare requisites.
Increasing cancer incidence is a significant driver of the Chemotherapy-Induced Neutropenia (CIN) Treatment Market. As cancer rates continue to rise globally, chemotherapy remains a primary treatment modality for many cancer patients. However, one of the most common and potentially life-threatening side effects of chemotherapy is neutropenia, which increases the risk of infections. Consequently, there is a growing demand for effective CIN treatments to manage neutropenic complications and minimize the risk of infections in cancer patients undergoing chemotherapy. With the increasing prevalence of cancer and the rising number of chemotherapy recipients, the demand for CIN treatments is expected to escalate, driving market growth as healthcare providers seek to address the challenges associated with chemotherapy-induced neutropenia and improve patient outcomes.
Growth factors and supportive care play a pivotal role in driving the Chemotherapy-Induced Neutropenia (CIN) Treatment Market. Granulocyte colony-stimulating factors (G-CSFs) and other growth factors are essential for stimulating the production of white blood cells, thereby mitigating the risk of neutropenia in cancer patients undergoing chemotherapy. Additionally, supportive care measures such as infection prevention strategies and antibiotic prophylaxis are crucial for managing neutropenic complications and reducing the risk of infections. As healthcare providers prioritize patient safety and seek to optimize chemotherapy outcomes, there is a growing demand for effective CIN treatments that encompass both growth factors and supportive care measures. This drives market growth as stakeholders recognize the importance of comprehensive approaches to managing chemotherapy-induced neutropenia and strive to improve patient care and outcomes in oncology practice.
For instance, Spectrum Pharmaceuticals, Inc. has obtained approval from the U.S. FDA for its ROLVEDON (eflapegrastim-xnst) injection. This medication is designed to reduce the occurrence of infection, particularly febrile neutropenia, in adult patients undergoing myelosuppressive anti-cancer treatment for non-myeloid malignancies, which is associated with a notable incidence of febrile neutropenia.
The Chemotherapy-Induced Neutropenia Treatment Market segmentation, based on type, includes Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy (G-CSF), Granulocyte Transfusion, and Others. In 2023, the Antibiotic Therapy segment dominated the market, accounting for 35% of market revenue due to its widespread use in preventing and managing infections associated with neutropenia. Antibiotics are commonly prescribed as prophylactic agents to reduce the risk of bacterial infections in cancer patients undergoing chemotherapy. Additionally, antibiotics play a crucial role in treating established infections in neutropenic patients. The high efficacy, relatively low cost, and broad availability of antibiotics contribute to their dominance in the CIN treatment market.
Granulocyte colony-stimulating factor (G-CSF) therapy is experiencing the highest Compound Annual Growth Rate (CAGR) in the Chemotherapy-Induced Neutropenia (CIN) Treatment Market due to its efficacy in stimulating the production of white blood cells, particularly neutrophils, to prevent and manage neutropenia. With an increasing number of cancer patients undergoing chemotherapy and the growing recognition of the importance of neutropenia management, there is a rising demand for G-CSF therapy. Additionally, advancements in G-CSF formulations and delivery methods further drive its adoption and market growth.
Figure 1: Chemotherapy-Induced Neutropenia Treatment Market, by Type, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Chemotherapy-Induced Neutropenia Treatment Market segmentation, based on distribution channel, includes Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. In 2023, the Hospital Pharmacies category generated the most income. These include the centralized procurement of medications and supportive care products by hospitals for cancer treatment, which often involves chemotherapy-induced neutropenia management. Additionally, hospitals serve as key treatment centers for cancer patients, where chemotherapy and supportive care are administered, leading to a higher demand for CIN treatments through hospital pharmacies compared to other distribution channels, such as retail pharmacies or online pharmacies.
Retail pharmacies distribution channels are experiencing the highest Compound Annual Growth Rate (CAGR) in the Chemotherapy-Induced Neutropenia (CIN) Treatment Market due to several factors. These include the increasing trend towards outpatient cancer care and the expansion of retail pharmacy networks, providing greater accessibility to CIN treatments for patients outside hospital settings. Moreover, advancements in healthcare policies and insurance coverage may encourage patients to seek CIN treatments through retail pharmacies, contributing to the channel's rapid growth in the market.
By region, the study provides the market insights into North America, Europe, Asia-Pacific, and the Rest of the World. North America has secured the largest market share in the Chemotherapy-Induced Neutropenia (CIN) Treatment Market due to several factors. These include a high prevalence of cancer, extensive utilization of chemotherapy in cancer treatment, and well-established healthcare infrastructure. Additionally, the region benefits from a strong presence of key market players, advanced research and development initiatives, and favorable reimbursement policies, all of which contribute to North America's dominance in the CIN treatment market.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.
Figure 2: Chemotherapy-Induced Neutropenia Treatment Market Share By Region 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Chemotherapy-Induced Neutropenia Treatment market accounts for the second-largest market share due to the widespread adoption of chemotherapy in cancer treatment. Europe has secured the second-largest market share in the Chemotherapy-Induced Neutropenia (CIN) Treatment Market due to several factors. These include a significant burden of cancer incidence, widespread adoption of chemotherapy in cancer treatment, and robust healthcare systems across European countries. Additionally, the region benefits from strong regulatory frameworks, well-established clinical guidelines, and high awareness of neutropenia management practices, contributing to the prominence of Europe in the CIN treatment market as a key player in the global landscape. Further, the German Chemotherapy-Induced Neutropenia Treatment market held the largest market share, and the UK Chemotherapy-Induced Neutropenia Treatment market was the fastest growing market in the European region.
The Asia-Pacific Chemotherapy-Induced Neutropenia Treatment Market is expected to grow at the fastest CAGR from 2024 to 2032. The Asia Pacific region is experiencing the highest Compound Annual Growth Rate (CAGR) in the Chemotherapy-Induced Neutropenia (CIN) Treatment Market due to several factors. These include the increasing prevalence of cancer in the region, rising adoption of chemotherapy as a treatment modality, and improving access to healthcare services. Additionally, advancements in healthcare infrastructure, growing investments in cancer care, and rising awareness of neutropenia management contribute to the rapid growth of the CIN treatment market in Asia Pacific. Moreover, China’s Chemotherapy-Induced Neutropenia Treatment market held the largest market share, and the Indian Chemotherapy-Induced Neutropenia Treatment market was the fastest growing market in the Asia-Pacific region.
Leading players in the Chemotherapy-Induced Neutropenia (CIN) Treatment Market are focused on strategic initiatives to maintain their competitive edge. These include product development and innovation to introduce novel therapies and formulations for managing neutropenia. Additionally, companies engage in partnerships and collaborations with healthcare institutions and research organizations to expand their market developments and enhance treatment outcomes. Moreover, efforts are directed towards market expansion into emerging regions and strengthening distribution networks to ensure the availability of CIN treatments to a broader patient population.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Chemotherapy-Induced Neutropenia Treatment industry to benefit clients and increase the market sector. In recent years, the Chemotherapy-Induced Neutropenia Treatment industry has offered some of the most significant advantages to Antibiotic Therapy. Major players in the Chemotherapy-Induced Neutropenia Treatment market, including Amgen Inc., Spectrum Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., Novartis AG, Mylan N.V., Biogen Inc., Johnson & Johnson, Merck & Co., Inc., and Others, are attempting to increase market demand by investing in research and development operations.
Amgen Inc. is a leading biotechnology company with a significant presence in the Chemotherapy-Induced Neutropenia (CIN) Treatment Market. Leveraging its expertise in biologics and oncology, Amgen develops and commercializes innovative therapies for managing neutropenia in cancer patients undergoing chemotherapy. Key products include granulocyte colony-stimulating factors (G-CSFs) such as Neulasta (peg filgrastim) and Neupogen (filgrastim), which stimulate the production of white blood cells to reduce the risk of neutropenic complications. Additionally, Amgen invests in research and development to advance novel treatment modalities and enhance patient outcomes in CIN management. With a global footprint and a commitment to oncology innovation, Amgen continues to play a pivotal role in addressing the challenges of chemotherapy-induced neutropenia.
Biogen Inc. is a renowned biotechnology company that contributes to the Chemotherapy-Induced Neutropenia (CIN) Treatment Market through its innovative therapies and research endeavors. With a focus on developing advanced biologic treatments, Biogen addresses the challenges of neutropenia management in cancer patients undergoing chemotherapy. While Biogen's primary focus lies in neurological disorders, its expertise in biologics and immunology enables the company to explore novel approaches for managing chemotherapy-induced neutropenia. Through strategic collaborations and investments in research and development, Biogen aims to expand its portfolio of therapies for CIN treatment, ultimately improving patient outcomes and quality of life. With a commitment to innovation and patient-centric care, Biogen continues to make significant contributions to the field of oncology and neutropenia management.
March 2023: Coherus BioSciences has been granted approval by the U.S. FDA for its pegfilgrastim-cbqv, marketed under the name Udencya, a biosimilar version of peg filgrastim. This medication is intended for the management of febrile neutropenia induced by chemotherapy.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.6 Billion |
| Market Size 2024 | USD 0.7 Billion |
| Market Size 2032 | USD 0.9 Billion |
| Compound Annual Growth Rate (CAGR) | 4.00% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Distribution Channel, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea |
| Key Companies Profiled | Amgen Inc., Spectrum Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., Novartis AG, Mylan N.V., Biogen Inc., Johnson & Johnson, Merck & Co., Inc. and Others |
| Key Market Opportunities | · Clinical Research and Development and Personalized Medicine Approaches |
| Key Market Dynamics | · Growing Aging Population and Increasing Cancer Incidence |
Frequently Asked Questions (FAQ) :
The Chemotherapy-Induced Neutropenia Treatment Market size was valued at USD 0.6 Billion in 2023.
The global market is projected to grow at a CAGR of 4.00% during the forecast period, 2024-2032.
North America had the largest share in the global market.
The key players in the market are Amgen Inc., Spectrum Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., Novartis AG, Mylan N.V., Biogen Inc., Johnson & Johnson, Merck & Co., Inc. and Others.
The Antibiotic Therapy category dominated the market in 2023.
Hospital Pharmacies had the largest share of the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
